PALI compared with BBNX: revenue, margins and what each company keeps, and the suppliers and customers both name

PALIPalisade Bio, Inc.

Mkt capRevenueRevenue

BBNXBeta Bionics, Inc.

Mkt capRevenueRevenue

Compare

PALIPalisade Bio, Inc.

BBNXBeta Bionics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

PALI1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▲+1.90%—

BBNX

0 of 3at or beyond implied

Reportimpliedrealized× implied

Q3 FY26—▼−16.55%—

Q2 FY26±27.9%▼−5.93%×0.21

= impliedPALI realized, solidBBNX realized, hatchedOne scale, both sides: full bar = 34%× = |realized| ÷ impliedSource: market data

Q1 FY26

±33.3%

▼−0.57%

×0.02

Feb 18 '26±26.0%▼−2.58%×0.10

PALIPalisade Bio, Inc.

1.17▼−1.97%· post 1.16

Mkt cap$202.2MRevenue$500,000Q2 FY26Revenue—

BBNXBeta Bionics, Inc.

16.78▼−4.57%· post 16.78

ClosedOct 30 '26

Mkt cap$779.6MRevenue$36MQ3 FY26Revenue$100MFY25

Compare

ClosedOct 30 '26

PALIPalisade Bio, Inc.

BBNXBeta Bionics, Inc.

1.17▼−1.97%post 1.16

Price

16.78▼−4.57%post 16.78

$202.2M

Mkt cap

$779.6M

Q2 FY26$500,000

Revenue

$36MQ3 FY26

—

Revenue

$100MFY25

PALI1.17▼−1.97%vsBBNX16.78▼−4.57%ClosedOct 30 '26